Quantcast

Latest Brain tumor Stories

2014-08-31 23:02:00

Doctors at Atlantic NeuroSurgical Specialists (ANS) have added a new and innovative form of therapy to their treatment arsenal in the battle against glioblastoma multiforme (GBM). Affecting nearly 10,000 Americans annually, GBM is the one of the most aggressive and difficult-to-control forms of primary brain tumors in the United States. Morristown, NJ (PRWEB) August 31, 2014 Describing the NovoTTFTM system as a “cell division taser device,” Dr. Yaron Moshel explains that the NovoTTF...

2014-08-28 08:27:58

SAN ANTONIO, Aug. 28, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the recent publication of the article "Targeting thapsigargin towards tumors" in the journal Steroids. The recent article co-authored by Doan, et al. (see full reference below), reviews the evolution and development of GenSpera's prodrug technology platform that is designed to deliver the potent, cytotoxic activity of...

2014-08-27 23:05:24

Twelve Early Career Scientists Selected to Receive ABTA Basic Research Fellowships and Discovery Grant Award Chicago, IL (PRWEB) August 27, 2014 The American Brain Tumor Association is pleased to announce the recipients of the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery Grant Awards. Through the funding of early career scientists, the ABTA is seeding the field with talented, bright young investigators who have the potential to change our understanding of the causes,...

2014-08-27 23:02:42

NovoTTF™-100A System Offers Novel, Non-Invasive Treatment in Fight Against an Aggressive Type of Brain Cancer Morristown,NJ (PRWEB) August 27, 2014 ANS is pleased to announce the availability of NovoTTF-100A System, a ground breaking anti-cancer therapy for the treatment of recurrent glioblastoma (GBM). Experts at ANS are now certified to prescribe this new medical therapy and will begin extending this new treatment option for recurrent GBM patients starting immediately. NovoTTF™...

2014-08-27 16:25:38

DelMar Is Advancing Clinical Trials With VAL-083 As A New Chemotherapy For Refractory Glioblastoma Multiforme VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Tuesday, September...

2014-08-26 08:31:13

Interim analysis of triple-blind, parallel-controlled trial proves intraoperative MRI more effective than conventional neurosurgery for certain brain tumors MINNEAPOLIS, Aug. 26, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that a recently published article in the journal Neurosurgery is the highest level clinical evidence to show that the use of VISIUS(®) intraoperative MRI (iMRI) in brain tumor surgery results in complete...

2014-08-24 12:20:34

CINCINNATI, Aug. 24, 2014 /PRNewswire-USNewswire/ -- An international research team reports in Nature Medicine a novel molecular pathway that causes an aggressive form of medulloblastoma, and suggests repurposing an anti-depressant medication to target the new pathway may help combat one of the most common brain cancers in children. http://photos.prnewswire.com/prnvar/20110406/MM79025LOGO The multi-institutional group, led by scientists at Cancer and Blood Diseases Institute (CBDI)...

2014-08-21 23:07:25

MarketResearchReports.Biz include new market research report "Glioblastoma Multiforme Therapeutics In Asia-Pacific Markets To 2020 - Novel Therapeutic Approaches Target High Unmet Need In Newly Diagnosed And Recurrent GBM" to its huge collection of research reports. View all Therapeutic Area Market Research Reports at http://www.marketresearchreports.biz/category/37. Albany, NY (PRWEB) August 21, 2014 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel...

2014-08-21 08:28:35

Japanese Society of Neuro-Oncology calls for rapid approval by the Japanese Ministry of Health and Welfare (MHLW) ST. HELIER, Jersey, Aug. 21, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that it has submitted the registration dossier for Pre-Market Approval (PMA) of the NovoTTF-100A System to treat recurrent glioblastoma to the Japanese Pharmaceutical and Medical Device Agency (PMDA). Glioblastoma is the most common and deadly form of primary...

2014-08-19 08:29:50

VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m(2) cohort VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 19, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m(2) has been opened at three clinical trial sites in the United...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'